We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Institute of Biomedical Research Corporation New (PK) | USOTC:MRES | OTCMarkets | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.0064 | 0.0052 | 0.0064 | 0.00 | 16:37:56 |
From Jul 2019 to Jul 2024
BASEL, Switzerland, Sept. 17 /PRNewswire-FirstCall/ - Neuro-Biotech Corp. (PINKSHEETS: MRES) (OTCQB: MRES) announces the nomination of Doctor Claude Poulin as President and CEO.
Mr Barry Somervail comments on today's announcement "Following the change of the Company's direction during the summer of 2010, I stayed on as a member of board of directors in order to facilitate the transition process, and now that this process is complete I am pleased to announce the relinquishment of my position and duties to Dr. Poulin.
Dr. Claude Poulin, 71, a general practitioner with over 40 years of experience, owns and operates a Lachute medical clinic where he continues to practice to this day. Dr. Poulin will bring his medical experience and expertise, as well as his knowledge of patients to the board. He is also looking forward to highlighting the value of the various applications of Neuro-Biotech products within the medical community.
The appointment of Dr. Claude Poulin became effective upon the filing of the 8k Form with the relevant authorities.
Forward Looking Statements
This release contains statements that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Act of 1995. Certain statements in this press release may contain words such as "anticipates," "believes," "could," "expects," "intends," "may," "projects," "targets" and other similar language that is considered forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties and persons reading this release are cautioned that such statements are only predictions, and that the Company's actual future results or performance may be materially different. The Company disclaims any intention or obligation to update or revise forward-looking information, whether as a result of new information, future events, or otherwise, could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
SOURCE Neuro-Biotech Corp.
Copyright . 17 PR Newswire
1 Year Institute of Biomedical ... (PK) Chart |
1 Month Institute of Biomedical ... (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
